Blog

Break Through Cancer – Launching the PoweRD 2 Cure ALK+ Lung Cancer TeamLab

Break Through Cancer logo

Dec 6, 2024, 18:47

Break Through Cancer – Launching the PoweRD 2 Cure ALK+ Lung Cancer TeamLab

“Today we launch the PoweRD 2 Cure ALK+ Lung Cancer TeamLab! Uniting researchers from Dana-Farber, MD Anderson Cancer Center, Koch Institute, Sidney Kimmel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Boston Children’s Hospital, Mass General Cancer Center, CU Cancer Center, Vanderbilt-Ingram Cancer Center in radical collaboration to target residual lung cancer cells remaining after initial therapy.”

Additional information.

Boston Children’s Hospital Break Through Cancer cancer CU Cancer Center Dana-Farber Koch Institute Mass General Cancer Center MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center OncoDaily Oncology Sidney Kimmel Comprehensive Cancer Center Vanderbilt-Ingram Cancer Center

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Special Coverage